Merck & Company Inc (MRK)
NYSE Market Closed
Merck & Co., Inc. is a global pharmaceutical company that develops and sells prescription medicines, vaccines, biologic therapies, and animal health products. The company, known as MSD outside the United States and Canada, operates across major therapeutic areas including oncology, infectious disease, cardiometabolic disorders, immunology, and vaccines. Its scale, research base, and commercial reach make it one of the most important drugmakers in the global healthcare sector.
Merck’s largest growth driver is its oncology franchise, led by Keytruda, an immunotherapy used across multiple cancer types. Keytruda works by helping the immune system recognize and attack cancer cells, and it has become central to modern cancer treatment in many indications. Beyond oncology, Merck has a significant vaccines business, including products used in pediatric immunization and Gardasil, which helps protect against diseases caused by human papillomavirus.
The company also participates in infectious disease treatment and prevention, as well as selected areas of cardiometabolic care. In addition to human health, Merck operates an animal health division that supplies medicines, vaccines, and related products for livestock and companion animals, adding diversification beyond its core pharmaceutical portfolio.
Merck’s financial performance depends on patent protection, clinical trial success, regulatory approvals, pricing dynamics, and global healthcare demand. The United States is a major market for its human health products, but the company also sells extensively internationally. For investors, Merck represents exposure to a large research-driven pharmaceutical business with a leading cancer platform, a durable vaccines portfolio, and a meaningful presence in animal health.
Last updated
- Market Cap
- $309,839,472,862
- P/E
- 34.68
- P/FCF
- 21.95
- P/S
- 4.71
- Enterprise Value
- $353,629,472,862
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
Schwab vs. Vanguard: Which Dividend ETF Is Best for Your Portfolio?
Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsight
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary
InVitria Showcases Exbumin® and Optibumin® 25 at IPEC Excipient World: Biologics Summit: Recombinant Human Serum Albumins Already Used in On-Market Approved Biologics
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
Zostavax Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
Rotateq Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $309,839,472,862
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $353,629,472,862
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 34.68
- P/B
P/B ratio compares a company's share price to its book value per share.
- 6.75
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 4.71
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 18.4
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 5.38
- EPS
- 3.62
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 2.66%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 21.95
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 17.32
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $14,115,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 19.48%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 6.94%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.07
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.3
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.06
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.2
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $11,304,837
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 125.45
Income Statement
| Line Item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Revenue | 16.29B | 16.32B | 17.18B | 15.8B | 15.62B |
| Gross profit | 13.34B | 11.51B | 12.99B | 11.95B | 11.73B |
| Operating income | -1.88B | 6.16B | 7.46B | 6.36B | 6.71B |
| EBITDA | -2.02B | 6.3B | 8.14B | 6.36B | 7.32B |
| Net income | -4.24B | 2.96B | 5.79B | 4.43B | 5.08B |
| Basic EPS | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — |
Balance Sheet
| Line Item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total assets | 128.69B | 136.87B | 129.55B | 117.52B | 115.12B |
| Total liabilities | 82.75B | 84.2B | 77.64B | 68.46B | 66.72B |
| Total equity | 45.88B | 52.61B | 51.85B | 48.99B | 48.34B |
| Cash & equivalents | 5.33B | 14.57B | 18.17B | 8.01B | 8.63B |
| Current assets | 35.02B | 43.52B | 47.56B | 37.07B | 35.5B |
| Current liabilities | 26.95B | 28.33B | 28.63B | 26.04B | 25.17B |
Cash Flow
| Line Item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Operating cash flow | 3.92B | 2.86B | 7.82B | 3.29B | 2.5B |
| Investing cash flow | -10.21B | -11.2B | -283M | -770M | -1.49B |
| Financing cash flow | -2.98B | 4.75B | 2.64B | -3.56B | -5.76B |
| Change in cash | -9.29B | -3.51B | 10.19B | -659M | -4.59B |
- EODHD filings mapper does not expose edgar_index parity from the SDK/API yet.
- EODHD filings mapper does not expose ten_k_section parity from the SDK/API yet.
- EODHD filings mapper does not expose eight_k_text parity from the SDK/API yet.
- EODHD filings mapper does not expose form_3 parity from the SDK/API yet.
| Kind | Filing | Date | Link |
|---|---|---|---|
| form 4 | Form 4 — Ro Khanna | View Filing | |
| form 4 | Form 4 — Chirfi Guindo | View Filing | |
| form 4 | Form 4 — Jennifer Zachary | View Filing | |
| form 4 | Form 4 — David Michael Williams | View Filing | |
| form 4 | Form 4 — Johannes Jacobus Oosthuizen | View Filing | |
| form 4 | Form 4 — Richard R Deluca | View Filing | |
| form 4 | Form 4 — Chirfi Guindo | View Filing | |
| form 4 | Form 4 — Dean Y Li | View Filing | |
| form 4 | Form 4 — Josh Gottheimer | View Filing | |
| form 4 | Form 4 — Robert M Davis | View Filing | |
| form 4 | Form 4 — Dalton E Smart III | View Filing | |
| form 4 | Form 4 — Caroline Litchfield | View Filing | |
| form 4 | Form 4 — Michael T. McCaul | View Filing | |
| form 4 | Form 4 — Gilbert Ray Cisneros, Jr. | View Filing | |
| form 4 | Form 4 — Julie Johnson | View Filing | |
| form 4 | Form 4 — Gilbert Ray Cisneros, Jr. | View Filing | |
| form 4 | Form 4 — Julie Johnson | View Filing | |
| form 4 | Form 4 — David Michael Williams | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free